Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Century Announces Phase 1/2 Trial of iNK Cell Therapy CNTY-101 in Autoimmune Diseases
Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy, intended for moderate to severe systemic lupus erythematosus.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Bain Capital Life Sciences
Deal Size : $60.0 million
Deal Type : Private Placement
Century Therapeutics Expands Autoimmune Pipeline Supported by $60M and Clade Acquisition
Details : Century intends to use the net proceeds to support the expansion of CNTY-101, a CD19-targeting iNK cell therapy, currently being evaluated in a clinical trial in B-cell malignancies.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 04, 2024
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Bain Capital Life Sciences
Deal Size : $60.0 million
Deal Type : Private Placement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Clade Therapeutics
Deal Size : $45.0 million
Deal Type : Acquisition
Century Therapeutics Strengthens Position in Autoimmune with Pipeline Expansion
Details : Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-EvasionTM platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $45.0 million
November 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Clade Therapeutics
Deal Size : $45.0 million
Deal Type : Acquisition
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 12, 2024
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Recipient : Fujifilm Cellular Dynamics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 11, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Recipient : Fujifilm Cellular Dynamics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : CNTY-101 is an investigational off-the-shelf cancer immunotherapy product candidate that utilizes iPSC-derived NK cells with a CD19-directed CAR and designed to overcome the three major pathways of host versus graft rejection - CD8+ T cells, CD4+ T cells...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 02, 2023
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy, administered via Intravenous Infusion, intended for moderate to severe systemic lupus erythematosus.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : CNTY-101
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CNTY-104
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Bristol Myers Squibb
Deal Size : $3,150.0 million
Deal Type : Collaboration
Details : Century will be responsible for discovery and preclinical development of CNTY-104, an iPSC-derived allogeneic cell therapies for hematologic and solid tumors. Bristol Myers Squibb will be responsible for clinical development and commercialization of firs...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $150.0 million
October 01, 2022
Lead Product(s) : CNTY-104
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Bristol Myers Squibb
Deal Size : $3,150.0 million
Deal Type : Collaboration
Details : CNTY-101 is the first allogeneic cell product candidate with six genetic modifications incorporated using sequential rounds of CRISPR-mediated homologous recombination and repair that has received IND clearance by the FDA.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 25, 2022
Century Therapeutics to Present at the SITC 37th Annual Meeting
Details : CNTY-101, targeting CD19 for relapsed, refractory B-cell lymphoma, is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, and an EGFR safety switch.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 10, 2022